These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Stancu IC; Vasconcelos B; Ris L; Wang P; Villers A; Peeraer E; Buist A; Terwel D; Baatsen P; Oyelami T; Pierrot N; Casteels C; Bormans G; Kienlen-Campard P; Octave JN; Moechars D; Dewachter I Acta Neuropathol; 2015 Jun; 129(6):875-94. PubMed ID: 25862635 [TBL] [Abstract][Full Text] [Related]
6. New Therapeutic Property of Dimebon as a Neuroprotective Agent. Ustyugov A; Shevtsova E; Ashraf GM; Tarasov VV; Bachurin SO; Aliev G Curr Med Chem; 2018; 25(39):5315-5326. PubMed ID: 27494393 [TBL] [Abstract][Full Text] [Related]
7. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087 [TBL] [Abstract][Full Text] [Related]
8. α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. Zhang YH; Wang DW; Xu SF; Zhang S; Fan YG; Yang YY; Guo SQ; Wang S; Guo T; Wang ZY; Guo C Redox Biol; 2018 Apr; 14():535-548. PubMed ID: 29126071 [TBL] [Abstract][Full Text] [Related]
9. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084 [TBL] [Abstract][Full Text] [Related]
10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011 [TBL] [Abstract][Full Text] [Related]
11. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Rodríguez-Navarro JA; Rodríguez L; Casarejos MJ; Solano RM; Gómez A; Perucho J; Cuervo AM; García de Yébenes J; Mena MA Neurobiol Dis; 2010 Sep; 39(3):423-38. PubMed ID: 20546895 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895 [TBL] [Abstract][Full Text] [Related]
13. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796 [TBL] [Abstract][Full Text] [Related]
14. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024 [TBL] [Abstract][Full Text] [Related]
15. [Study into molecular targets of a neuroprotective compound dimebon using a transgenic mice line]. Shelkovnikova TA; Ustiugov AA; Kokhan VS; Tarasova TV; Medvedeva VK; Khritankova IV; Bachurin SO; Ninkina NN Biomed Khim; 2014; 60(3):354-63. PubMed ID: 25019398 [TBL] [Abstract][Full Text] [Related]
16. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Brunden KR; Trojanowski JQ; Lee VM Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442 [TBL] [Abstract][Full Text] [Related]
17. Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine). Ustyugov A; Shevtsova E; Bachurin S Mol Neurobiol; 2015 Oct; 52(2):970-8. PubMed ID: 26123670 [TBL] [Abstract][Full Text] [Related]
18. Effects of alpha-tocopherol on an animal model of tauopathies. Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189 [TBL] [Abstract][Full Text] [Related]
19. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. Baazaoui N; Iqbal K J Alzheimers Dis; 2017; 58(1):215-230. PubMed ID: 28387677 [TBL] [Abstract][Full Text] [Related]
20. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Wagner J; Krauss S; Shi S; Ryazanov S; Steffen J; Miklitz C; Leonov A; Kleinknecht A; Göricke B; Weishaupt JH; Weckbecker D; Reiner AM; Zinth W; Levin J; Ehninger D; Remy S; Kretzschmar HA; Griesinger C; Giese A; Fuhrmann M Acta Neuropathol; 2015 Nov; 130(5):619-31. PubMed ID: 26439832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]